Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous

Related Experiment Video

Updated: Jul 2, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Richard J Gumina1, Eric H Yang, Gurpreet S Sandhu

  • 1Ohio State University, Columbus, USA.

Mayo Clinic Proceedings
|September 9, 2008
PubMed

Insights

Combining glycoprotein (GP) IIb/IIIa inhibitors with clopidogrel during percutaneous coronary interventions (PCI) significantly lowers 30-day and long-term mortality. This dual antiplatelet therapy approach improves survival rates in patients undergoing PCI.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents used in percutaneous coronary interventions (PCI).
  • Concomitant use with clopidogrel, a P2Y12 inhibitor, represents a dual antiplatelet therapy (DAPT) strategy.
  • Understanding the clinical outcomes of this combined regimen in ad hoc PCI is crucial for optimizing patient management.

Purpose of the Study:

  • To evaluate the impact of GP IIb/IIIa inhibitors combined with clopidogrel on clinical outcomes.
  • To assess both short-term (30-day) and long-term mortality in patients undergoing ad hoc PCI.

Main Methods:

  • A retrospective study of patients undergoing elective or urgent ad hoc PCI between March 1998 and December 2006.
  • Stratification of patients based on the administration of GP IIb/IIIa inhibitors with concomitant clopidogrel.
  • Propensity score analysis was employed to adjust for baseline differences and confounding factors.

Main Results:

  • Long-term mortality was significantly lower in patients receiving GP IIb/IIIa inhibitors at the time of PCI (P<.001).
  • After propensity adjustments, a significant reduction in 30-day mortality was observed (HR, 0.56; P=.01).
  • Long-term survival significantly improved with GP IIb/IIIa inhibitor use, persisting after adjustments (HR, 0.88; P=.021).
  • Patients treated with drug-eluting stents showed improved adjusted long-term mortality.

Conclusions:

  • Coadministration of GP IIb/IIIa inhibitors and dual antiplatelet therapy is associated with reduced risk-adjusted mortality in ad hoc PCI.
  • This combination therapy appears to be a safe and effective strategy for improving survival in this patient population.
Abstract

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...